Quarter
Charts

ENTRADA THERAPEUTICS, INC. — Key Metrics

3 years of history · ending 2025-12-31 · SEC EDGAR

Income StatementCash FlowBalance SheetKey Metrics

Forensics

Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.

F-Score (Piotroski 0-9)

Z-Score (Altman; <1.81 = distress)

Per Share Metrics

Expense Ratios

Working Capital Analysis

Valuation Multiples

Cash-Flow Multiples

Enterprise Value Multiples

52-Week Range

Trailing Returns

ROIC vs WACC

Yields

Capital Deployment Yields

Liquidity & Leverage Ratios

Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)

EPS (Diluted)
$-3
Book Value Per Share
$7
Free Cash Flow Per Share
$-3
Cash Per Share
$2
Revenue Per Share
$1
OCF Per Share
$-3
Return on Equity
-39.1%
Return on Assets
-31.8%
Return on Invested Capital
-34.0%
Current Ratio
12.53
Quick Ratio
12.53
Asset Turnover
0.06
R&D / Revenue
559.7%
SBC / Revenue
77.1%
Capex / Revenue
4.1%
Working Capital
$282M
Net Current Asset Value
$235M
Invested Capital
$306M
OCF / Net Income
0.89
FCF / Net Income
0.90
Accruals Ratio (Sloan)
-4.0%
Net Debt
$-90M
Net Debt / EBITDA
0.59
Capex Coverage
-123.45
Tangible Common Equity
$306M
TCE / Total Assets
81.1%
NOPAT
$-125M
Cash ROIC
-35.3%
WC / Revenue
1108.5%
Capex / D&A
0.25
Reinvestment Rate
1.9%
Asset Growth vs Revenue Growth
59.6%
Stock Price (FY-end)
$10
Market Cap
$425M
P/E Ratio
10.28
P/S Ratio
16.73
P/B Ratio
1.39
P/TB Ratio
1.39
P/OCF Ratio
3.57
P/FCF Ratio
3.72
Enterprise Value
$335M
EV / EBITDA
11.29
EV / Sales
13.17
EV / FCF
3.21
FCF Yield
-30.5%
Shareholder Yield
-4.6%
R&D Yield
33.5%
Capex Yield
0.2%
Graham Number
$20
Shares Variation (YoY)
6.1%
Beta (5Y)
1.04
Cost of Equity
9.7%
52W High
$18
52W Low
$5
Trailing Return 1Y
-41.0%
F-Score (Piotroski)
2.00
Z-Score (Altman)
2.15

Earnings Forecasts

Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).

Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.

EPS — Consensus vs Actual

Revenue — Consensus vs Actual

Beat / Miss vs Estimate

Stock Price on Earnings Dates

ENTRADA THERAPEUTICS, INC. — Effective Tax Rate ReconciliationNEW

Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.

Effective Rate Trend

Reconciliation LineFY2020FY2021FY2022FY2023FY2024FY2025
Federal Statutory Rate21.00%21.00%21.00%21.00%21.00%21.00%
State & Local Income Taxes6.20%6.10%5.50%5.00%3.20%6.80%
Foreign Rate Differential——————
Other Adjustments——0.00%-2.00%0.00%—
R&D Tax Credits4.00%3.90%-5.00%50.00%8.20%-4.40%
Nondeductible Expenses-0.20%-0.30%-1.40%11.00%2.80%-1.70%
Valuation Allowance Change-31.00%-30.70%-30.10%1.70%-22.50%-31.70%
Effective Tax Rate—0.00%0.00%1.55%1.30%-0.60%

Cash vs Accrual

ItemFY2020FY2021FY2022FY2023FY2024FY2025
Income Tax Expense (Accrual)———$18.7M$859.0K$924.0K
Income Taxes Paid (Cash)———$14.7M$4.6M$1.7M